Patents by Inventor Jay T. Evans

Jay T. Evans has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220144865
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Publication number: 20220144833
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: January 24, 2022
    Publication date: May 12, 2022
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Patent number: 11274115
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Grant
    Filed: September 5, 2017
    Date of Patent: March 15, 2022
    Assignee: GLAXOSMITHKLINE BIOLOGICAL SA
    Inventors: Helene G. Bazin-Lee, Jay T. Evans, David Burkhart, Michael Cochran, David A. Johnson
  • Publication number: 20210277038
    Abstract: This invention relates inter alia to novel imidazoquinoline derivatives and their use in therapy, particularly as vaccine adjuvants.
    Type: Application
    Filed: September 5, 2016
    Publication date: September 9, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, S.A.
    Inventors: Helene G. BAZIN-LEE, Jay T. EVANS, David BURKHART, Michael COCHRAN, David A. JOHNSON
  • Publication number: 20210077618
    Abstract: The invention relates to compounds of formula (I) and their use in eliciting a pro-Thl7 immune response. Further provided are methods of production of said compounds. (Formula I) wherein m is an integer between 4 and 13; n is an integer between 4 and 13; x is an integer between 4 and 13; y is an integer between 4 and 13.
    Type: Application
    Filed: April 12, 2019
    Publication date: March 18, 2021
    Applicant: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: Jay T EVANS, Alyson SMITH
  • Publication number: 20180318415
    Abstract: The invention relates to a composition comprising solid lipid nanoparticles (SLNs), wherein the SLNs comprise an aminoalkyl glucosaminide phosphate (AGP).
    Type: Application
    Filed: December 6, 2016
    Publication date: November 8, 2018
    Applicant: GLAXOSMITHKLINE BIOLOGICALS, SA
    Inventors: David BURKHART, Jay T. Evans, Hardeep OBEROI, Yvonne M. YORGENSEN
  • Publication number: 20170072033
    Abstract: A liposomal composition comprising lipids which form a liposomal lipid bilayer, with phospholipid-PEG conjugates incorporated into the liposomal lipid bi-layer, and a chitosan or chitosan derivative is described and claimed.
    Type: Application
    Filed: March 12, 2015
    Publication date: March 16, 2017
    Inventors: Nupur DUTTA, Hardeep OBEROI, David BURKHARD, Jay T EVANS
  • Publication number: 20170072050
    Abstract: Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF-biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.
    Type: Application
    Filed: April 20, 2016
    Publication date: March 16, 2017
    Inventors: William S. BOWEN, Jay T. EVANS, Melinda M. HUTTON, David A. JOHNSON, Laurie A. MINNS
  • Publication number: 20170071967
    Abstract: A liposomal composition comprising a liposome and an aminoalkansulfonic buffer is described and claimed.
    Type: Application
    Filed: March 12, 2015
    Publication date: March 16, 2017
    Inventors: Nupur DUTTA, Hardeep OBEROI, David BURKHART, Jay T EVANS
  • Publication number: 20150004180
    Abstract: Compositions comprising a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF-biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.
    Type: Application
    Filed: December 23, 2013
    Publication date: January 1, 2015
    Applicant: GLAXOSMITHKLINE BIOLOGICALS S.A.
    Inventors: WILLIAM S. BOWEN, Jay T. EVANS, MELINDA M. HUTTON, DAVID A. JOHNSON, LAURIE A. MINNS
  • Patent number: 8629116
    Abstract: The use of a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: January 14, 2014
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: William S. Bowen, Jay T. Evans, Melinda M. Hutton, David A. Johnson, Laurie A. Minns
  • Publication number: 20110257113
    Abstract: The use of a selected aminoalkyl glusoaminide 4-phosphate (AGP) CRX-547 to induce a TRIF biased response in a human system, which results in reduced levels of MyD88-dependent cytokines relative to the MyD88-dependent cytokines induced by its diastereomer AGP CRX-527.
    Type: Application
    Filed: December 23, 2009
    Publication date: October 20, 2011
    Inventors: William S. Bowen, Jay T. Evans, Melinda M. Hutton, David A. Johnson, Laurie A. Minns
  • Publication number: 20030190333
    Abstract: The invention provides pharmaceutical compositions, particularly vaccine compositions, employing an adjuvant system comprising at least one aminoalkyl glucosaminide phosphate compound and at least one saponin compound. Such compositions synergistically enhance the immune response in a mammal to a co-administered antigen. Also provided are methods of using the compositions in the treatment of various human diseases, including cancer, microbial infections and autoimmune disorders.
    Type: Application
    Filed: February 4, 2002
    Publication date: October 9, 2003
    Applicant: Corixa Corporation
    Inventors: Sally Mossman, Lawrence Evans, Jory R. Baldridge, Jay T. Evans
  • Publication number: 20030108565
    Abstract: Hydrophobic ion pairing (HIP) is applied to solubilize proteins and/or adjuvants in an organic medium. A polymer is cosolubilized in the medium and microspheres encapsulating the protein and/or adjuvant can be produced by a single emulsion method. Microspheres prepared by this method exhibit low initial burst of the protein and gradual release over time, and elicit a strong and comprehensive immune response. Compositions comprising a protein and an adjuvant co-encapsulated in microspheres are provided.
    Type: Application
    Filed: July 10, 2002
    Publication date: June 12, 2003
    Inventors: Mark E. Johnson, Jay T. Evans, Jeffrey A. Kern